Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Data: Axios research; Graphic: Andrew Witherspoon/Axios

Serbia joined Argentina, Belarus and Russia this week to be among the first countries to approve and administer Russia's Sputnik V vaccine.

The big picture: Russia has blazed its own course in the vaccine race, relying entirely on a single, state-funded vaccine that was given emergency authorization before much data was available about its effectiveness.

  • The vaccine's developers say it has a 91% efficacy rate, though that's yet to be confirmed by a medical journal or international regulator.

Now, Russia is seeking to vaccinate its population while also exporting doses around the world. The government says 1 million Russians have been vaccinated, but it has fallen far behind the number of doses it promised to deliver to cities and regions by now, per the WSJ.

  • German Chancellor Angela Merkel told Vladimir Putin on Wednesday that she is open to manufacturing doses of the vaccine in Germany, if it's approved by EU health regulators.
  • But a Hungarian government spokesman said last week that Hungary was no longer planning to rely on the Sputnik vaccine due to Russia's "inadequate manufacturing capacity" — instead focusing on vaccines provided by the EU and sourced from another world power: China.

The state of play: Health regulators in China recently approved the country's first homegrown vaccine, developed by the state-owned pharmaceutical company Sinopharm, for general use.

  • The UAE, Bahrain, Pakistan and Morocco are among those slated to receive Sinopharm doses, while Turkey, Indonesia and Brazil have preordered a vaccine developed by another Chinese company called Sinovac Biotech.
  • Regulators in Brazil announced Thursday that the Sinovac vaccine is 78% effective. Sinopharm says its vaccine is 79% effective, based on preliminary data.

What to watch: If China's vaccines prove effective — and the country can manufacture sufficient quantities to cover domestic needs and significant exports to the developing world — that could markedly improve the outlook for global vaccination in the coming years. It could also offer China a significant soft power boost.

  • Part of the reason that so many countries are lining up for doses of the Pfizer and Moderna vaccines is that the more expensive Pfizer and Moderna vaccines are bound almost exclusively for the rich world.

Go deeper:

Go deeper

Jan 30, 2021 - World

Germany to impose travel restrictions to curb spread of coronavirus variants

Border police officers check passports and COVID-19 tests at Frankfurt Airport. Photo: Thomas Lohnes via Getty Images

Germany announced Friday that it was imposing new travel restrictions in an effort to curb the spread of more contagious coronavirus variants.

Details: All non-German residents traveling from countries deemed "areas of variant concern," including the United Kingdom, South Africa, Portugal, Ireland, Brazil, Lesotho and Eswatini, will be banned from entering the country, even if they test negative for the coronavirus.

Jan 30, 2021 - World

Science helps New Zealand avoid another coronavirus lockdown

New Zealand Prime Minister Jacinda Ardern (L) visits a lab at Auckland University in December. Photo: Phil Walter/Getty Images

New Zealand has avoided locking down for a second time over COVID-19 community cases because of a swift, science-led response.

Why it matters: The Health Ministry said in an email to Axios Friday there's "no evidence of community transmission" despite three people testing positive after leaving managed hotel isolation. That means Kiwis can continue to visit bars, restaurants and events as much of the world remains on lockdown.

Super typhoon Surigae explodes to Cat. 5 intensity

Super Typhoon Surigae seen on satellite imagery Saturday morning east of the Philippines. (CIRA/RAMMB)

Super Typhoon Surigae surged in intensity from a Category 1 storm on Friday to a beastly Category 5 monster on Saturday, with maximum sustained winds estimated at 190 mph with higher gusts.

Why it matters: This storm — known as Typhoon Bising in the Philippines — is just the latest of many tropical cyclones to undergo a process known as rapid intensification, a feat that studies show is becoming more common due to climate change.